Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD
In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-VID-230011 Approved October 2023.

New Prostate Cancer Screening Guidelines – Case-Based Explanation for GP

Acute Migraine Management

Continuous Glucose Monitoring Update – Why it will Soon Become Standard Care

Faecal Calprotectin – A Practical Guide to the Test and the New Item Number

expert
Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital